-
公开(公告)号：WO2008024188A3
公开(公告)日：2008-09-04
申请号：PCT/US2007017340
申请日：2007-08-03
Applicant: ABBOTT LAB , WU CHENGBIN , GHAYUR TARIQ , DIXON RICHARD W , SALFELD JOCHEN G
Inventor： WU CHENGBIN , GHAYUR TARIQ , DIXON RICHARD W , SALFELD JOCHEN G
IPC: A61K39/00
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K47/42 , A61K47/48384 , A61K47/6803 , A61K51/1093 , A61K2039/505 , C07K16/22 , C07K16/24 , C07K16/241 , C07K16/244 , C07K16/245 , C07K16/2809 , C07K16/2887 , C07K16/2896 , C07K16/40 , C07K16/46 , C07K16/467 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/522 , C07K2317/56 , C07K2317/64 , C07K2317/76
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，特别涉及其用于预防和/或治疗急性和慢性炎症和其它疾病的用途。
-
公开(公告)号：WO2007117465A3
公开(公告)日：2008-08-28
申请号：PCT/US2007008307
申请日：2007-04-02
Applicant: ABBOTT LAB , ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
公开(公告)号：WO2008060621A2
公开(公告)日：2008-05-22
申请号：PCT/US2007024076
申请日：2007-11-16
Applicant: ABBOTT LAB , GEORGE DAWN M , DIXON RICHARD W , FRIEDMAN MICHAEL , HOBSON ADRIAN , LI BIQIN , WANG LU , WU XIAOYUN , WISHART NEIL
Inventor： GEORGE DAWN M , DIXON RICHARD W , FRIEDMAN MICHAEL , HOBSON ADRIAN , LI BIQIN , WANG LU , WU XIAOYUN , WISHART NEIL
IPC: C07D471/04 , A61K31/4375 , A61K31/438 , A61K31/454 , C07D401/04
CPC classification number: A61K31/454 , A61K31/437 , A61K31/438 , A61K31/4545 , A61K31/4709 , A61K31/4747 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/55 , A61K31/553 , C07D207/14 , C07D401/04 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D487/14
Abstract: The present invention is directed to novel aminopyrrolidines of formula I, pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
Abstract translation: 本发明涉及式I的新型氨基吡咯烷，其药学上可接受的盐，其代谢物，其异构体，其立体异构体或其前体药物，其中变量如本文所定义。 式（I）化合物可用作趋化因子受体拮抗剂，因此可用于治疗某些病症和疾病，特别是炎性病症和疾病以及增殖性疾病和病症，例如癌症。
-
公开(公告)号：WO2008127271A3
公开(公告)日：2009-04-09
申请号：PCT/US2007019660
申请日：2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hTL-13活性有害的病症的人类受试者中。
-
公开(公告)号：WO2007005608A3
公开(公告)日：2008-10-09
申请号：PCT/US2006025584
申请日：2006-06-29
Applicant: ABBOTT LAB , LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
Inventor： LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K2317/24 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869
Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.
Abstract translation: 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。
-
Patent Agency Ranking
公开(公告)号：EP1907421A4
公开(公告)日：2012-03-28
申请号：EP06785967
申请日：2006-06-29
Applicant: ABBOTT LAB
Inventor： LACY SUSAN E , FUNG EMMA , BELK JONATHAN P , DIXON RICHARD W , ROGUSKA MICHAEL , HINTON PAUL R , KUMAR SHANKAR
IPC: C07K16/24
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K2317/24 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6869
-
公开(公告)号：EP1928237A4
公开(公告)日：2011-03-09
申请号：EP06824879
申请日：2006-09-01
Applicant: ABBOTT LAB
Inventor： BREINLINGER ERIC C , CALDERWOOD DAVID J , FRANK KRISTINE E , BETSCHMANN PATRICK , HIRST GAVIN C , MORYTKO MICHAEL J , DIXON RICHARD W
IPC: A01N43/50
CPC classification number: C07D487/04
-
公开(公告)号：EP2001480A4
公开(公告)日：2011-06-15
申请号：EP07754773
申请日：2007-04-02
Applicant: ABBOTT LAB
Inventor： ERICSSON ANNA M , BURCHAT ANDREW , FRANK KRISTINE E , CALDERWOOD DAVID J , ABBOTT LILY K , ARGIRIADI MARIA A , BORHANI DAVID W , CUSACK KEVIN P , DIXON RICHARD W , GORDON THOMAS D , MULLEN KELLY D , TALANIAN ROBERT V , WU XIAOYUN , ZHANG XIAOLEI , WANG LU X , LI BIQIN , BARBERIS CLAUDE E , WISHART NEIL
IPC: A61K31/196 , A61P35/00 , C07D403/12
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
-
19.发明公开
公开(公告)号：EP1928506A4
公开(公告)日：2009-10-21
申请号：EP06813554
申请日：2006-08-18
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , GHAYUR TARIQ , DIXON RICHARD W , SALFELD JOCHEN G
CPC classification number: C07K16/241 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/244 , C07K16/28 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/64 , C07K2317/94
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.
Abstract translation: 本发明涉及工程化的多价和多特异性结合蛋白，制备方法，特别涉及其用于预防和/或治疗急性和慢性炎症和其它疾病的用途。
-
公开(公告)号：EP2099454A4
公开(公告)日：2010-11-10
申请号：EP07867491
申请日：2007-11-16
Applicant: ABBOTT LAB
Inventor： GEORGE DAWN M , DIXON RICHARD W , FRIEDMAN MICHAEL , HOBSON ADRIAN , LI BIQIN , WANG LU , WU XIAOYUN , WISHART NEIL
IPC: A61K31/445 , C07D211/00
CPC classification number: A61K31/454 , A61K31/437 , A61K31/438 , A61K31/4545 , A61K31/4709 , A61K31/4747 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K31/55 , A61K31/553 , C07D207/14 , C07D401/04 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D487/14
-
-
-
-
-
-
-
-
-
Search Results
82
records
(took 0.023 seconds)
